GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (NSE:ZYDUSLIFE) » Definitions » PB Ratio

Zydus Lifesciences (NSE:ZYDUSLIFE) PB Ratio : 5.30 (As of May. 30, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-30), Zydus Lifesciences's share price is ₹1044.75. Zydus Lifesciences's Book Value per Share for the quarter that ended in Mar. 2024 was ₹197.07. Hence, Zydus Lifesciences's PB Ratio of today is 5.30.

The historical rank and industry rank for Zydus Lifesciences's PB Ratio or its related term are showing as below:

NSE:ZYDUSLIFE' s PB Ratio Range Over the Past 10 Years
Min: 2.02   Med: 4.49   Max: 9.13
Current: 5.3

During the past 13 years, Zydus Lifesciences's highest PB Ratio was 9.13. The lowest was 2.02. And the median was 4.49.

NSE:ZYDUSLIFE's PB Ratio is ranked worse than
86.06% of 954 companies
in the Drug Manufacturers industry
Industry Median: 1.945 vs NSE:ZYDUSLIFE: 5.30

During the past 12 months, Zydus Lifesciences's average Book Value Per Share Growth Rate was 13.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 15.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 16.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 18.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zydus Lifesciences was 27.90% per year. The lowest was -6.90% per year. And the median was 19.80% per year.

Back to Basics: PB Ratio


Zydus Lifesciences PB Ratio Historical Data

The historical data trend for Zydus Lifesciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences PB Ratio Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 3.47 2.10 2.84 5.11

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.84 - 3.32 - 5.11

Competitive Comparison of Zydus Lifesciences's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's PB Ratio falls into.



Zydus Lifesciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Zydus Lifesciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=1044.75/197.067
=5.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Zydus Lifesciences  (NSE:ZYDUSLIFE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Zydus Lifesciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (NSE:ZYDUSLIFE) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (NSE:ZYDUSLIFE) Headlines

No Headlines